natgillin/translations-raw huggingface dataset:
Clinical trials in subjects with genotype 4 chronic hepatitis C PEARL- I- genotype 4, treatment-naïve or pegIFN + RBV experienced without cirrhosis Design: 
PEARL- I- genotip 4, še nezdravljeni ali že zdravljeni s kombinacijo pegIFN + RBV, brez ciroze
Expected: ↓ombitasvir ↓ paritaprevir ↓ dasabuvir 
Pričakovano: ↓ dasabuvir ↓ ombitasvir ↓ paritaprevir
The pharmacokinetic properties of the combination of Viekirax with dasabuvir have been evaluated in healthy adult subjects and in subjects with chronic hepatitis C. Table 19 shows mean Cmax and AUC of Viekirax 25 mg/150 mg/100 mg once daily with dasabuvir 250 mg twice daily following multiple doses with food in healthy volunteers. 
Farmakokinetične lastnosti kombinacije zdravila Viekirax in dasabuvirja so ocenili pri zdravih odraslih in pri bolnikih s kroničnim hepatitisom C. Preglednica 18 prikazuje povprečni Cmax in AUC za zdravilo
SVR12 for genotype 1a-infected treatment-naïve subjects in PEARL IV 
SVR12 pri še nezdravljenih preiskovancih, okuženih z genotipom 1a, v preskušanju PEARL IV
Dabigatran etexilate 
Pričakovano: ↑ dabigatran eteksilat
HCV genotype 1b 
HCV Genotip 1b Viekirax in dasabuvir
↑ paritaprevir ↑ dasabuvir 
Pričakovano: ↑ ombitasvir ↑ paritaprevir ↑ dasabuvir
CYP3A4 inhibition by protease inhibitors. 
Zdravila, ki zavrejo CYP3A4 in prenašalne proteine
No dose adjustment needed for Viekirax with or without dasabuvir. 
Prilagoditev odmerka za zdravilo Viekirax z ali brez dasabuvirja ni potrebna.
No dose adjustment is necessary for raltegravir or Viekirax with or without dasabuvir. 
Prilagoditev odmerka raltegravirja ali zdravila Viekirax z dasabuvirjem ali brez njega ni potrebna.
Mechanism: BCRP inhibition by paritaprevir, ritonavir and dasabuvir. 
Zavrtje BCRP s paritaprevirjem, ritonavirjem in dasabuvirjem
Expected: ↑ sildenafil 
Pričakovano: ↑ amiodaron
Mechanism: Increase in paritaprevir exposures may be due to inhibition of CYP3A/efflu x transporters by lopinavir and higher dose of ritonavir 
CYP3A/iztočni h prenašalcev z lopinavirjem in večjim odmerkom ritonavirja
No dose adjustment is necessary for methadone and Viekirax with or without dasabuvir. 
Prilagoditev odmerka metadona in zdravila Viekirax z dasabuvirjem ali brez
Viekirax with or without dasabuvir ethinylestradiol 
Viekirax z dasabuvirje m ali brez njega etinilestradiol
↑ imatinib 
↑ trazodon
Increase in raltegravir exposures may be due to UGT1A1 inhibition by paritaprevir, ombitasvir. 
Večja izpostavljenost raltegravirju je morda posledica zavrtja
No dose adjustment of Viekirax with and without dasabuvir is required for patients with mild, moderate or severe renal impairment , or end-stage-renal disease on dialysis (see section 4.2). 
Bolnikom, ki imajo blago, zmerno ali hudo okvaro ledvic ali ledvično odpoved in so na dializi, odmerka zdravila Viekirax z dasabuvirjem ali brez njega ni potrebno prilagoditi (glejte poglavje 4.2).
Viekirax and dasabuvir with weight-based ribavirin for 12 weeks 
Zdravljenje: Viekirax in dasabuvir z ribavirinom, odvisnim od telesne mase, 12 tednov
20 mg single dose 
DIURETIKI furosemid enkraten odmerek 20 mg
Diazepam2 mg single dose 
Enkraten odmerek 2 mg
INHALED BETA AGONISTS Salmeterol 
AGONISTI ADRENERGIČNIH RECEPTORJEV BETA
(Invented) name 
Izmišljeno ime Jakost
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/. 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu
Vaccination may interfere with existing sero-epidemiological surveys. 
Cepljenje lahko vpliva na obstoječe serološko-epidemiološke študije.
1 x 1 dose 2 x 1 dose 5 x 1 dose 10 x 1 dose 
1 x 1 odmerek 2 x 1 odmerek 5 x 1 odmerek 10 x 1 odmerek
Lot {number} 
Lot{številka}
Box of 1, 2, 5 or 10 vial(s) of 1 dose. 
Škatla z 1, 2, 5 ali 10 vialo(ami) z 1 odmerkom.
Date of first authorisation: 05/08/2011 Date of last renewal: 17/05/2016 
Datum pridobitve dovoljenja za promet: 05/08/2011 Datum podaljšanja dovoljenja za promet: 17/05/2016
Store and transport refrigerated (2 °C-8 °C). 
Shranjujte in prevažajte v hladilniku (2 °C-8 °C).
• Revaccination: a sufficient degree of protection should be achieved after an annual booster injection with a single dose although this schedule has not been fully validated. 
• Revakcinacija: Zadostna zaščita je naj bi bila zagotovljena po revakcinaciji z enim odmerkom cepiva letno, čeprav ta program cepljenja še ni bil dokončno validiran.
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities. 
Odpadne snovi odstranite s prekuhavanjem, sežigom ali potopitvijo v ustreznem dezinfekcijskem sredstvu, katerega uporabo odobrijo pristojni organi.
If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon. 
Če opazite kakršne koli resne neželene učinke ali druge učinke, ki niso omenjeni v teh navodilih za uporabo, obvestite svojega veterinarja.
A hypersensitivity reaction may occur in rare cases, which may require appropriate symptomatic treatment. 
V redkih primerih lahko pride do preobčutljivostne reakcije, ki jo je potrebno ustrezno simptomatično zdraviti.
EU/2/11/129/001 1 x 1 dose EU/2/11/129/002 2 x 1 dose EU/2/11/129/003 5 x 1 dose EU/2/11/129/004 10 x 1 dose 
EU/2/11/129/001 1 x 1 odmerek EU/2/11/129/002 2 x 1 odmerek EU/2/11/129/003 5 x 1 odmerek EU/2/11/129/004 10 x 1 odmerek
EXP {month/year} Use immediately after opening 
EXP {mesec/leto} Uporabite takoj po prvem odpiranju.
ATC vet code: QI05AX. 
Oznaka ATCvet: QI05AX
• Primary vaccination course: first injection from 5 months of age, second injection 4-6 weeks later, 
• Primarno cepljenje: prvi odmerek od starosti petih mesecev, drugi odmerek 4 do 6 tednov pozneje.
The safety of the vaccine has been demonstrated in foals from 5 months of age. 
Varnost cepiva je bila dokazana pri žrebetih starejših od 5 mesecev.
Sodium chloride Disodium phosphate dihydrate Potassium dihydrogen phosphate Water for injections 
Natrijev hidrogenfosfat dihidrat Kalijev dihidrogenfosfat Voda za injekcije
Shelf life of the veterinary medicinal product as packaged for sale: 27 months. 
Rok uporabnosti zdravila v pakiranju za prodajo: 27 mesecev.
Any person intending to manufacture, import, possess, sell, supply and use Proteq West Nile must consult the relevant Member State's competent authority on the current vaccination policies prior to the manufacture, import, possession, sale, supply and/or use. 
Vsakdo, ki namerava izdelovati, uvažati oziroma vnašati, posedovati, prodajati, oskrbovati in/ali uporabljati Proteq West Nile, se mora posvetovati s pristojnim organom posamezne države članice o veljavnih programih cepljenja še pred izdelavo, uvozom, posedovanjem, prodajo, oskrbo in/ali uporabo.
The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product. 
SPC, tabela 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št. 470/2009.
The manufacture, import, possession, sale, supply and/or use of Proteq West Nile may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation. 
Izdelava, uvoz/vnos, posedovanje, prodaja, oskrba in/ali uporaba Proteq West Nile je lahko v državi članici prepovedana na njenem celotnem ozemlju ali delu ozemlja v skladu z nacionalno zakonodajo.
Pharmacotherapeutic group: Immunologicals for equidae, other immunologicals. 
Farmakoterapevtska skupina: Imunološka zdravila za konje, druga imunološka zdravila.
Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest France 
Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest Francija
However, since the IgM response following vaccination is infrequent, a positive IgM-ELISA test result is a strong indicator of natural infection with West Nile Virus. 
Ker pa je IgM odgovor po cepljenju redek, je pozitivna IgM- ELISA pomemben pokazatelj naravne okužbe z virusom West Nile.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP. 
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na zunanji ovojnini, po EXP.
Administer one dose of 1 ml, by intramuscular injection, preferably in the neck region, according to the following schedule: 
Injicirajte 1 odmerek (1 ml) intramuskularno, priporočljivo v predel vratu, po naslednjem razporedu:
To stimulate active immunity against West Nile virus. 
Cepivo spodbuja aktivno imunost proti virusu West Nile.
Type I glass vial, with a butyl elastomer closure, sealed with an aluminium cap. 
Viala iz stekla tipa I z zamaškom iz butilnega elastomera in aluminijasto zaporko.
Onset of immunity: 4 weeks after the first dose of the primary vaccination course. 
Nastop imunosti: 4 tedne po prvem odmerku primarnega cepljenja.
In order to achieve full protection, the full vaccination course of two doses must be given. 
Za popolno zaščito sta potrebna dva odmerka.
Duration of immunity: 1 year after a full primary vaccination course of two injections. 
Čas trajanja imunosti: 1 leto po popolnem primarnem cepljenju (dva odmerka).
The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009. 
Učinkovina biološkega izvora namenjena vzbujanju aktivne imunosti, ni vključena v Uredbo (ES) št.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 
Pogostost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (pojavijo se pri več kot 1 živali od 10 živali med enim zdravljenjem) - pogosti (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 100 živali) - občasni (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 1.000 živali) - redki (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 10.000 živali) - zelo redki (pojavijo se pri manj kot 1 živali od 10.000 živali, vključujoč posamezne primere).
Each dose of 1 ml contains: 
Vsak odmerek (1 ml) vsebuje:
Proteq West Nile suspension for injection for horses 
Proteq West Nile suspenzija za injiciranje za konje
The vaccine strain vCP2017 is a recombinant canarypox virus expressing the preM/E genes of West Nile virus. 
Sev cepiva vCP2017 je rekombinanten Canarypox virus, ki izraža predM/E gene virusa West Nile.
Pregnancy and lactation: This vaccine can be used during pregnancy and lactation. 
Brejost in laktacija: Lahko se uporablja v obdobju brejosti in laktacije.
A slight increase in temperature (max. 1.5 °C) may occur in rare cases for 1 day, exceptionally 2 days. 
Redko se lahko pojavi rahlo povišanje temperature (največ 1,5 °C), ki lahko traja 1 dan, izjemoma 2 dni.
INDICATIONS 
INDIKACIJA
However, the vaccine has also been shown to be safe in a field study including animals of 2 months of age. 
Vendar se je cepivo tudi v terenskem poskusu na žrebetih starih 2 meseca pokazalo za varno.
After inoculation, the virus does not multiply in the horse but expresses the protective proteins. 
Po inokulaciji se virus v konjih ne razmnožuje, ampak izraža zaščitne proteine, ki spodbudijo imunost proti virusu West Nile.
Proteq West Nile suspension for injection 
Proteq West Nile suspenzija za injiciranje
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALCI BIOLOŠKE ZDRAVILNE UČINKOVINE IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE
If infection is suspected as a result of a positive IgM response, additional testing would need to be conducted to conclusively determine whether the animal was infected or vaccinated. 
Če je sum na okužbo postavljen na podlagi pozitivnega IgM odziva, je priporočljivo dodatno dokazovanje, ali je prišlo do naravne okužbe ali je odziv posledica cepljenja.
Active immunisation of horses from 5 months of age against West Nile disease by reducing the number of viraemic horses. 
Aktivna imunizacija konj, starih 5 mesecev ali več proti bolezni West Nile za zmanjšanje števila viremičnih konjev oziroma za zmanjšanje resnosti in trajanja kliničnih znakov, če so ti že prisotni.
Active substance: 
Zdravilni učinkovini:
DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION 
ODMEREK ZA POSAMEZNE ŽIVALSKE VRSTE TER NAČIN UPORABE IN
Apathy, usually resolving within two days, and reduced appetite may be observed in rare cases the day after vaccination. 
V redkih primerih se lahko dan po cepljenju pojavita apatičnosti in zmanjšan tek.
A transient swelling (max. diameter 5 cm) which resolves within 4 days may appear commonly at the injection site. 
Na mestu injiciranja se lahko pogosto pojavi prehodna oteklina (s premerom največ 5 cm), ki izgine v 4 dneh.
Pain and local hyperthermia can occur in rare cases. 
V redkih primerih se lahko pojavita bolečina in lokalno povišana temperatura.
Carbomer ......................................................................................................................................... 4 mg For the full list of excipients, see section 6.1. 
Karbomer ................................................................................................................................................. 4 mg Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
No adverse reactions other than those already mentioned in section 4.6 have been observed after the administration of more than 10 doses. 
Po dajanju desetkratnega odmerka niso ugotovili nobenih drugih neželenih učinkov razen tistih, navedenih v poglavju 4.6.
Homogeneous opalescent suspension. 
Suspenzija za injiciranje Homogena opalescentna suspenzija.
West Nile recombinant canarypox virus (vCP2017) ....................................... 6.0 to 7.8 log10 CCID*50 * Cell culture infectious dose 50% 
West Nile rekombinantni Canarypox virus (vCP2017)… ...................................... 6.0 do 7.8 log10 FAID*50
West Nile recombinant canarypox virus (vCP2017) ....................................... 6.0 to 7.8 log10 CCID*50 * Cell culture infectious dose 50 % 
West Nile rekombinantni Canarypox virus (vCP2017)… ................................ 6.0 do 7.8 log10 FAID*50
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial Label 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
West Nile (vCP2017) ........................................................................................ 6.0 to 7.8 log10 CCID50 
West Nile (vCP2017)… ..................................................................................... 6.0 do 7.8 log10 FAID50
No adverse reactions other than those already mentioned in the section “Adverse Reactions” have been observed after the administration of more than 10 doses. 
Po dajanju 10 odmerkov niso ugotovili nobenih drugih stranskih učinkov razen tistih, navedenih v poglavju »Neželeni učinki«.
Store and transport refrigerated Do not freeze 
Shranjujte in prevažajte v hladilniku.
Read the package leaflet before use 
Pred uporabo preberite navodila za uporabo.
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. STATEMENT OF THE MRLs 
SERIJE B. POGOJI TER OMEJITVE GLEDE OSKRBE IN UPORABE
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENT 
NAVEDBA ZDRAVILNE UČINKOVIN(E) IN DRUGE(IH) SESTAVIN(E)
50 mg/g 
dermalna uporaba 50 mg/g
The frequency of adverse reactions is defined using the following convention: 
Pogostost neželenih učinkov je opredeljena po naslednjem dogovoru:
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) http://www.ema.europa.eu/.
Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg. 
Ne uporabite pri živalih, mlajših od 6 tednov, in mačkah, lažjih od 2 kg.
Dogs: i.v. 
Psi: i.v.
In dogs, these side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. 
Pri psih se našteti neželeni škodljivi učinki pretežno pojavijo v prvem tednu zdravljenja, so večinoma prehodni in po končanem zdravljenju minejo, vendar so lahko v zelo redkih primerih tudi resni ali smrtno nevarni.
Date of first authorisation: 09/12/2008 Date of last renewal:09/12/2013 
Datum podaljšanja dovoljenja za promet: 09/12/2013
The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see 4.3). 
Varnost veterinarskega zdravila v obdobju brejosti in laktacije še ni raziskana (glejte poglavje 4.3).
See section “Contraindications”. 
Glejte poglavje Kontraindikacije.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine. 
Približno 75 % vnesenega odmerka se izloči z blatom, preostala količina pa z urinom.
A clear yellow solution. 
Prozorna rumena raztopina.
Interactions with other medicinal products and other forms of interaction 
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously. 
Pri določanju obdobja brez zdravljenja je treba upoštevati tudi farmakološke lastnosti zdravil, ki smo jih dajali predhodno.
Meloxicam is eliminated with a half-life of 24 hours in dogs and 15 hours in cats. 
Razpolovna doba izločanja meloksikama je pri psih 24 ur, pri mačkah pa 15 ur.
Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams) ATCvet code: QM01AC06 
Farmakoterapevtska skupina protivnetna in protirevmatična zdravila, nesteroidna (oksikami) Oznaka ATC vet QM01AC06
Do not use in case of hypersensitivity to the active substance or to any of the excipients. 
Ne uporabite v primeru preobčutljivosti na zdravilno učinkovino ali katero koli pomožno snov.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. 
Predzdravljenje z zdravili s protivnetnim delovanjem lahko povzroči dodatne neželene učinke ali jih okrepi, zato teh zdravil ne smemo dajati najmanj 24 ur pred začetkom zdravljenja.
Musculo-skeletal disorders: single subcutaneous injection. 
Mišično-skeletna obolenja: enkratna podkožna injekcija.
In the case of over dosage symptomatic treatment should be initiated. 
Pri prevelikem odmerjanju je treba uvesti simptomatsko zdravljenje.
For post-operative pain relief in cats, safety has only been documented after thiopental/halothane anaesthesia. 
Pri lajšanju pooperativne bolečine pri mačkah je varnost dokumentirana samo za anestezijo s tiopentalom in halotanom.
Acticam 5 mg/ml solution for injection for dogs and cats. 
Acticam 5 mg/ml, raztopina za injiciranje za pse in mačke.
People with known hypersensitivity to meloxicam should avoid contact with the veterinary medicinal product. 
Osebe z znano preobčutljivostjo za nesteroidna protivnetna zdravila naj se izogibajo stiku z zdravilom.
Once broached use by ... 
Načeto zdravilo uporabite do ...
Acticam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. 
Acticama ne smemo dajati z drugimi nesteroidnimi protivnetnimi zdravili ali glukokortikosteroidi.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. 
Ne uporabite pri živalih z obolenji prebavil, kot so zdraženost prebavil in krvavitev, pri motnjah jetrne, srčne ali ledvične funkcije in hemoragičnih obolenjih.
Ethanol anhydrous Poloxamer 188 Glycofurol Meglumine Glycine 
Poloksamer 188 Glikofurol Meglumin Glicin
Pregnancy / Lactation 
Brejost/Laktacija
Avoid introduction of contamination during use. 
Paziti je treba, da med uporabo ne bi prišlo do okužbe.
Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73 μg/ml in dogs and 1.1 μg/ml in cats were reached approximately 2.5 hours and 1.5 hours post administration, respectively. 
Meloksikam je po podkožnem dajanju v celoti biološko uporaben in doseže največjo srednjo koncentracijo v plazmi, ki je 0,73 μg/ml pri psih in 1,1 μg/ml pri mačkah, približno 2,5 ure oz. 1,5 ure po dajanju.
SPECIAL WARNINGS, IF NECESSARY 
POSEBNO(A) OPOZORILO(A), ČE JE/SO POTREBNO(A)
Colourless type I glass injection vial of 10 ml, closed with a grey EPDM rubber stopper and sealed with a flip off aluminium seal. 
Brezbarvne steklene injekcijske viale po 10 ml, zaprte z gumijastim zamaškom in aluminijasto zaporko.
Pack sizes: Single 10 ml injection vial. 
Navedena pakiranja Injekcijska viala po 10 ml.
Lot: {number} 
Lot {številka}
PACKAGE LEAFLET Acticam 5 mg/ml solution for injection for dogs and cats 
NAVODILO ZA UPORABO Acticam 5 mg/ml, raztopina za injiciranje za pse in mačke
or s.c. Cats: s.c. 
Mačke: s.c.
Do not use after the expiry date stated on the carton and the vial. 
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti (EXP), navedenega na zunanji ovojnini in viali.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary 
4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če je potrebno) Pri prevelikem odmerjanju uvedemo simptomatsko zdravljenje.
Reduction of post-operative pain (over a period of 24 hours): single intravenous or subcutaneous injection before surgery, for example at the time of induction of anaesthesia. 
Lajšanje pooperativne bolečine (v 24-urnem obdobju): enkratna intravenska ali podkožna injekcija pred operacijo, na primer ob indukciji anestezije.
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery: single subcutaneous injection before surgery, for example at the time of induction of anaesthesia. 
Lajšanje pooperativne bolečine po ovariohisterektomiji in manjših operacijah mehkega tkiva: enkratna podkožna injekcija pred operacijo, na primer ob indukciji anestezije.
− very rare (less than 1 animal in 10,000 animals, including isolated reports). 
− zelo redki (manj kot 1 od 10.000 živali, vključno s posameznimi poročili).
4.2 Indications for use, specifying the target species 
4.2 Indikacije za uporabo pri ciljnih živalskih vrstah Psi:
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER IMETNIKA DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVORNEGA ZA SPROŠČANJE SERIJ V EGP, ČE STA RAZLIČNA Imetnik dovoljenja za promet z zdravilom
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OR USE 
B POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM TER OMEJITVE GLEDE OSKRBE IN UPORABE
In dogs, in very rare cases, haemorrhagic diarrhoea, haematemesis and gastrointestinal ulceration have been reported. 
Pri psih so zelo redko poročali o hemoragični driski, hematemezi in razjedi prebavil.
In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. 
Pri živalih, pri katerih je večja verjetnost, da bodo potrebovale anestezijo (npr. pri starejših živalih), je treba presoditi o potrebi po intravenskem ali podkožnem dajanju tekočine med anestezijo.